Pakistan, July 18 -- Pakistan's national drug regulator has officially approved the marketing of a generic version of the potent antibiotic Daptomycin, made by a Chinese drug maker, in a move that could provide a new, potentially more affordable option for treating severe, drug-resistant infections.

The Drug Regulatory Authority of Pakistan (DRAP) granted the market approval for the injectable drug, manufactured by China-based Hainan Poly Pharm, the Chinese firm announced in a post, according to Gwadar Pro.

This development is significant for Pakistan, a country facing a severe public health crisis from antimicrobial resistance (AMR).

According to a 2019 global study by The Lancet, drug-resistant infections are the third-leading cause ...